

Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144

Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2024-25/71 September 17, 2024

To, Listing/ Compliance Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Dear Sir/Madam,

BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
"Exchange Plaza", Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015.

Sub: Newspaper Advertisement

Please find enclosed copies of newspaper advertisement with respect to extension in the Buyback offer period, published in following newspapers on Tuesday, September 17, 2024:

- Financial Express (English Edition)
- Jansatta (Hindi Edition)
- Navshakti (Marathi Edition)

A copy of the Newspaper advertisement is also available on the website of the Company at www.aartidrugs.co.in

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M. No.: F12932

Place: Mumbai

Date: Monday, September 16, 2024

FINANCIAL EXPRESS

Summary statement of price information of past issues (during current financial year and two financial years preceding the current financial year) No. of IPOs trading at Premium No. of IPOs trading at Discount No. of IPOs trading at Premium No. of IPOs trading at Discount Total Amount of **Total Number** Sr. No. 30th calendar days from Listing 180th calendar days from Listing 180th calendar days from Listing 30th calendar days from Listing **Funds Raise** of IPOs (₹ in Crores) Over 50% Between 25-50% Less than 25% A. Main Board Exchange B. Small and Medium Enterprises Exchange 2022-2023 Nil Not Applicable 2023-2024 ₹114.95 2 2024-2025 ₹88.96 Not Applicable Not Applicable Not Applicable Not Applicable

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

For Paramount Speciality Forgings Limited On behalf of the Board of Directors

Ms. Ankita Anil Patankar

Company Secretary and Compliance Officer

Paramount Speciality Forgings Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the Red Herring Prospectus with RoC on Monday, September 09, 2024. The Red Herring Prospectus shall be available on the website of SEBI at www.nseindia.com, website of the Company at www.paramountforge.com and on the websites of the Book Running Lead Manager at www.swarajshares.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see 'Risk Factors' on page 30 of the Red Herring Prospectus. Potential Bidders should not rely on the Draft Red Herring Prospectus and Addendum filed with NSE for making any investment decision and instead should place reliance on the Red Herring Prospectus.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States absent registration under the U.S. Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) in the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

Aarti Drugs Ltd.



Name of the Scheme(s)



Nippon Life India Asset Management Limited

(CIN - L65910MH1995PLC220793)

Registered Office: 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai - 400 013. Tel No. +91 022 6808 7000

Fax No. +91 022 6808 7097 • mf.nipponindiaim.com

NOTICE NO. 46



(₹ per unit)* | 2024 (₹ per unit)

NAV as on

September 13,

Amount of

Distribution

Notice is hereby given that the Trustee of Nippon India Mutual Fund ("NIMF") has approved the following Distribution under Income Distribution cum capital withdrawal (IDCW) option of undernoted schemes of NIMF, with September 20, 2024 as the record date:

	(per dille)	ZOZ+ (* per dine)
Nippon India Corporate Bond Fund - Direct Plan-Quarterly IDCW Plan	0.2583	12.2610
Nippon India Corporate Bond Fund - Quarterly IDCW Plan	0.2457	12.1029
Nippon India Income Fund - Direct Plan-Quarterly IDCW Plan	0.3340	14.0573
Nippon India Income Fund - Quarterly IDCW Plan	0.2919	13.3252
Nippon India Income Fund - Half-Yearly IDCW Plan	0.5347	12.8618
Nippon India Income Fund - Direct Plan-Half Yearly IDCW Plan	0.6304	13.8746
Nippon India Short Term Fund - Direct Plan-Quarterly IDCW Plan	0.3144	15.3993
Nippon India Short Term Fund - Quarterly IDCW Plan	0.2881	15.0377
Nippon India Hybrid Bond Fund^^ - Quarterly IDCW Plan	0.2626	12.3080
Nippon India Hybrid Bond Fund^^ - Direct Plan-Quarterly IDCW Plan	0.2984	12.9523
Nippon India Dynamic Bond Fund - Quarterly IDCW Plan	0.2605	10.5350
Nippon India Dynamic Bond Fund - Direct Plan-Quarterly IDCW Plan	0.2723	10.6440
Nippon India Floating Rate Fund - Direct Plan-Quarterly IDCW Plan	0.2152	10.9873
Nippon India Floating Rate Fund - Quarterly IDCW Plan	0.2101	11.0904
Nippon India Credit Risk Fund^^ - Direct Plan-Quarterly IDCW Plan	0.2703	13.6950
Nippon India Credit Risk Fund^^ - Quarterly IDCW Plan	0.2369	13.0963
Nippon India Banking & PSU Debt Fund - Direct Plan-Quarterly IDCW Plan	0.2195	10.9621
Nippon India Banking & PSU Debt Fund - Quarterly IDCW Plan	0.2087	10.8987
Nippon India Nivesh Lakshya Fund - Direct Plan-Quarterly IDCW Plan	0.2649	11.7312
Nippon India Nivesh Lakshya Fund - Quarterly IDCW Plan	0.2132	11.6755
Nippon India Nivesh Lakshya Fund - Half-Yearly IDCW Plan	0.6370	12.5888
Nippon India Nivesh Lakshya Fund - Direct Plan-Half Yearly IDCW Plan	0.6558	12.6357
Nippon India Ultra Short Duration Fund^ - Direct Plan-Quarterly IDCW Plan	19.5747	1034.5721
Nippon India Ultra Short Duration Fund^ - Quarterly IDCW Plan	17.4736	1026.3969
Nippon India Liquid Fund - Direct Plan-Quarterly IDCW Plan	17.7873	1020.9474\$
Nippon India Liquid Fund - Quarterly IDCW Plan	17.4022	1019.1648\$
Nippon India Liquid Fund - Retail Quarterly IDCW Plan	19.2059	1232.0892\$
Nippon India Money Market Fund - Quarterly IDCW Plan	18.7153	1026.4230
Nippon India Money Market Fund - Direct Plan-Quarterly IDCW Plan	19.0590	1026.6720
Nippon India Low Duration Fund - Direct Plan-Quarterly IDCW Plan	19.5644	1030.4543
Nippon India Low Duration Fund - Retail Quarterly IDCW Plan	17.6271	1028.5729
Nippon India Low Duration Fund - Quarterly IDCW Plan	18.0678	1028.8855
Nippon India Overnight Fund - Quarterly IDCW Plan	1.6114	101.8005 ^{\$}
Nippon India Overnight Fund - Direct Plan-Quarterly IDCW Plan Note: Pursuant to notification issued by Government of Maharashtra in relation to	1.6360	101.8257\$

Note: Pursuant to notification issued by Government of Maharashtra in relation to change in a public holiday from September 16, 2024 to September 18, 2024 and to comply with guidelines for record date declaration, all above schemes of NIMF having IDCWs declaration scheduled for September 19, 2024 (Record Date) has now been shifted to subsequent working day i.e. September 20, 2024.

*Income distribution will be done, net of tax deducted at source, as applicable.

#or the immediately following Business Day if that day is a non-business day ^Number of Segregated Portfolio – 1, ^^Number of Segregated Portfolio – 2

^{\$} NAV as on September 15, 2024

Mumbai

September 16, 2024

Face value of all the above mentioned schemes is Rs. 10 per unit except for Nippon India Low Duration Fund, Nippon India Liquid Fund, Nippon India Ultra Short Duration Fund & Nippon India Money Market Fund which is Rs.1000 per unit and Nippon India Overnight Fund which is Rs.100 per unit

Pursuant to payment of dividend/IDCW, the NAV of the Schemes will fall to the extent of payout, and statutory levy, if any. The IDCW payout will be to the extent of above mentioned Distribution amount per unit or to the extent of available distributable surplus, as on the Record Date mentioned above, whichever is lower.

For units in demat form: IDCW will be paid to those Unitholders/Beneficial Owners whose names appear in the statement of beneficial owners maintained by the Depositories under the IDCW Plan/Option of the Schemes as on record date.

All unit holders under the IDCW Plan/Option of the above mentioned schemes, whose names appear on the

register of unit holders on the aforesaid record date, will be entitled to receive the IDCW. For Nippon Life India Asset Management Limited

(Asset Management Company for Nippon India Mutual Fund)

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Good gets better

Authorised Signatory



CIN: L37060MH1984PLC055433

Registered Office: Plot No. - N-198, M.I.D.C. Tarapur, Village - Pamtermbhi, Taluka & Dist. Palghar - 401 506, Maharashtra

Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D. Road No. 29, Sion (East), Mumbai - 400 022, Maharashtra Contact Person: Rushikesh Deole, Company Secretary & Compliance Officer

Email: investorrelations@aartidrugs.com; Website: www.aartidrugs.co.in

Tel. No.: +91 22 2404 8199; Fax: +91 22 2407 3462

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION BUYBACK CLOSING DATE: THURSDAY, SEPTEMBER 19, 2024

OFFER TO BUYBACK OF UP TO 6,65,000 (SIX LAKHS SIXTY-FIVE THOUSAND) FULLY PAID UP EQUITY SHARES OF AARTI DRUGS LIMITED ("COMPANY") HAVING A FACE VALUE OF ₹10/- (RUPEES TEN ONLY) EACH ("EQUITY SHARES") AT A PRICE OF ₹900/-(RUPEES NINE HUNDRED ONLY) PER FULLY PAID UP EQUITY SHARE IN CASH ON A PROPORTIONATE BASIS FROM ALL EQUITY SHAREHOLDERS/BENEFICIAL OWNERS OF THE EQUITY SHARES OF THE COMPANY THROUGH THE TENDER OFFER PROCESS USING THE STOCK EXCHANGE MECHANISM.

THIS ADDENDUM (THE "ADDENDUM") SHOULD BE READ IN CONJUNCTION WITH THE LETTER OF OFFER DATED SEPTEMBER 09, 2024. CAPITALISED TERMS USED IN THIS ADDENDUM AND NOT DEFINED HEREIN SHALL HAVE THE SAME MEANING AS ASCRIBED IN THE LETTER OF OFFER, EQUITY SHAREHOLDERS ARE REQUESTED TO NOTE THE FOLLOWING CHANGES / AMENDEMENT TO THE LETTER TO OFFER.

- 1. In connection with the captioned Buyback, the Letter of Offer in terms of the Buyback Regulations was dispatched to all Equity Shareholders on September 09, 2024.
- 2. In terms of the Buyback Regulations the tendering period of the Buyback is required to be kept open for a period of 5 (five) working days, and the Buyback Closing Date was identified as Wednesday, September 18, 2024, since Monday, September 16, 2024 was a public
- India Limited and circular bearing notice no. 20240914-5 dated September 14, 2024 issued by the BSE Limited, Monday, September 16, 2024 is no longer a public holiday and instead Wednesday, September 18, 2024, is a public holiday. On account of change in working day from September 16, 2024 to September 18, 2024, SEBI vide its email dated September 15,

Subsequently, vide circular bearing reference number 106/2024 dated September 14, 2024 issued by the National Stock Exchange of

- 2024 has allowed extension in the tendering period by 1 (one) working day. Accordingly, the Buyback Closing Date will be Thursday, September 19, 2024 instead of Wednesday, September 18, 2024. Please note that the Eligible shareholders will be able to tender in the Buyback on September 16, 2024 and September 19, 2024.
- Equity Shareholders are requested to note the following amendments in the Letter of Offer:
- 5.1 On the Cover Page of the Letter of Offer:

Buyback Closes on: Wednesday, September 18, 2024 to be replaced with Thursday, September 19, 2024

"The Last Date and time for Receipt of completed Tender Forms and other specific documents by the Registrar to the Buyback will be Thursday, September 19, 2024 instead of Wednesday, September 18, 2024."

5.2 The definition of "Buyback Closing Date" on page 3 of the Letter of Offer shall be replaced with: "Thursday, September 19, 2024."

5.3 The definition of "Tendering Period / Offer Period /" on page 6 of the Letter of Offer shall be replaced with: "Period of 6(six) Working Days from the Buyback Opening Date i.e. Wednesday, September 11, 2024 till Buyback Closing Date i.e. Thursday, September 19, 2024 (both days inclusive)."

5.4 Point no. 18.2 Collection Centre on page 63 of the Letter of Offer shall be replaced with:

"Eligible Shareholders are requested to submit their Tender Form(s) and requisite documents either by registered post / speed post to the Registrar to the Buyback, superscribing the envelope as "Aarti Drugs Limited -Buyback Offer-2024", or hand deliver the same to the Registrar to the Buyback at the address mentioned in paragraph above during office hours between 10.00 a.m. to 5.00 p.m. from Monday to Friday (except holidays, if any), so that the same are received on or before the Buyback Closing Date i.e. Thursday, September 19, 2024 (by 5 PM)."

5.5 Point 20.23 The Rejection Criteria point on page 73 of the Letter of Offer for the Eligible Shareholders holding Equity Shares in the physical form the point (a) shall be replaced with:

"If the documents mentioned in the Tender Form for Eligible Shareholders holding Equity Shares in physical form are not received by the Registrar on or before Thursday, September 19, 2024 by 5.00 p.m.;*

5.6 The schedule of activities on page 1 of the Letter of Offer shall be replaced with:

Activity	Day and Date	
Date of the Board Meeting approving the proposal for Buyback of Equity Shares	Monday, August 26, 2024	
Date of Public Announcement	Tuesday, August 27, 2024	
Date of publication of Public Announcement for the Buyback	Wednesday, August 28, 2024	
Record Date for determining the Buyback Entitlement and the names of Eligible Shareholders	Thursday, September 5, 2024	
Buyback opens on / Buyback Opening Date	Wednesday, September 11, 2024	
Buyback closes on / Buyback Closing Date	Thursday, September 19, 2024	
Last date of receipt of completed Tender Forms and other specified documents including physical share certificates (if and as applicable) by the Registrar to Buyback	Thursday, September 19, 2024	
Last date of verification by Registrar to Buyback	Friday, September 20, 2024	
Last date of intimation to the stock exchange regarding Acceptance or non-Acceptance of tendered Equity Shares by the Registrar and Manager to the Buyback	Wednesday, September 25, 2024	
Last date of settlement of bids on the stock exchange	Thursday, September 26, 2024	
Last date of dispatch of share certificate(s) by Registrar to Buyback / return of unaccepted demat shares by Stock Exchange to Seller Member/Eligible Shareholders	Thursday, September 26, 2024	
Last date of extinguishment of Equity Shares bought back	Tuesday, October 8, 2024	

Except as detailed in this Addendum, all other information and terms of Buyback as disclosed in the Letter of Offer remain unchanged. A copy of this Addendum will also be available on the websites of the website of the company at www.aartidrugs.co.in the website of the Manger of the Offer at www.ingaventures.com on the website of SEBI at www.sebi.gov.in and on website of the Stock Exchanges at www.bseindia.com and www.nseindia.com.

> MANAGER TO THE BUYBACK **LINK** Intime

Inga Ventures Private Limited

Address: 1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400069 Tel. no.: +91 022 6854 0808

Contact person: Kavita Shah Email: kavita@ingaventures.com Website: www.ingaventures.com SEBI registration no.: INM000012698 Validity period: Permanent

CIN: U67100MH2018PTC318359

Address: C 101, 1st Floor, 247 Park, L B S Marg, Vikhroli West, Mumbai - 400083, Maharashtra, India Tel. no.: +91 810 811 4949; Fax no.: +91 22 4918 6195 Contact person: Ms. Shanti Gopalkrishnan

Link Intime India Private Limited

Email: aartidrugs.buyback2024@linkintime.co.in Website: www.linkintime.co.in SEBI registration no.: INR000004058 Validity period: Permanent CIN: U67190MH1999PTC118368

For and on behalf of the Board of Directors of Aarti Drugs Limited

Sd/-Prakash M. Patil Chairman, Managing Director & CEO DIN: 00005618

Sd/-Harit P. Shah Whole Time Director DIN: 00005501

Sd/-Rushikesh Deole Company Secretary & Compliance Officer M.no: F12932

Date: September 16, 2024 Place: Mumbai



